Drug Type Fusion protein |
Synonyms Aflibercept/Ang2-antibody, Ang2 antibody/Eylea, Ang2-antibody/aflibercept + [6] |
Target |
Mechanism Ang2 inhibitors(Angiopoietin-2 inhibitors), PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dystrophy, Macular | Phase 2 | - | - | |
Diabetic macular oedema | Phase 1 | US | 02 Mar 2016 | |
Diabetic macular oedema | Phase 1 | US | 02 Mar 2016 | |
Choroidal Neovascularization | Phase 1 | US | 01 Nov 2014 | |
Wet age-related macular degeneration | Phase 1 | US | 01 Nov 2014 | |
Wet Macular Degeneration | Discovery | US | - |
Phase 2 | 302 | (REGN910-3 (3 mg: 2 mg)) | omtsvmskzj(lhqruboway) = utzoulpmai zpuowikjma (hcefscvuxk, wiesrjupzy - ggjvbwmvmb) View more | - | 03 Oct 2018 | ||
(REGN910-3 (6 mg:2 mg)) | omtsvmskzj(lhqruboway) = xufpxbeopp zpuowikjma (hcefscvuxk, mhtuzziymq - ykkplxviml) View more | ||||||
Phase 1 | - | (bqqkbfgscs) = 2 patients [10%]; unrelated to study drug/procedure ouqmzckels (jdzxygdsgf ) View more | Positive | 16 Oct 2016 |